5




## **CLAIMS**

## Weyclaim:

- 1. A method of screening drug candidates comprising:
  - a) providing a cell that expresses an expression profile gene encoding BFA4 or fragment thereof;
  - b) adding a drug candidate to said cell; and
  - c) determining the effect of said drug candidate on the expression of said expression profile gene.
- 2. A method according to <u>claim 1</u> wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.
- 3. A method of screening for a bioactive agent capable of binding to BFA4 or a fragment thereof, said method comprising:
  - a) combining said BFA4 or a fragment thereof and a candidate bioactive agent; and
  - b) determining the binding of said candidate agent to said BFA4 or a fragment thereof.
- 4. A method for screening for a bioactive agent capable of modulating the activity of BFA4, said method comprising:
  - a) combining BFA4 and a candidate bioactive agent; and
  - b) determining the effect of said candidate agent on the bioactivity of BFA4.
- 5. A method of evaluating the effect of a candidate breast cancer drug comprising:
  - a) administering said drug to a patient;
  - b) removing a cell sample from said patient; and
  - c) determining the expression of a gene encoding BFA4 or fragment thereof.
- 6. A method according to claim 5 further comprising comparing said expression profile to an expression profile of a healthy individual.
- 7. A method of diagnosing breast cancer comprising:
  - a) determining the expression of a gene encoding BFA4 or a fragment thereof in a first breast tissue of a first individual, and
  - b) comparing said expression of said gene(s) from a second normal breast tissue from said first individual or a second unaffected individual;

25

5



- 8. An antibody which specifically binds to BFA4 or a fragment thereof.
- 9. The antibody of Claim 8, wherein said antibody is a monoclonal antibody.
- 10. The antibody of Claim 8, wherein said antibody is a humanized antibody.
- 11. The antibody of Claim 8, wherein said antibody is an antibody fragment.
- 12. The antibody of Claim 8, wherein said antibody modulates the bioactivity of BFA4.
- 13. The antibody of Claim 12, wherein said antibody is capable of inhibiting the bioactivity or neutralizing the effect of BFA4.
- 14. A method for screening for a bioactive agent capable of interfering with the binding of BFA4 or a fragment thereof and an antibody which binds to BFA4 or fragment thereof, said method comprising:
  - a) combining BFA4 or fragment thereof, a candidate bioactive agent and an antibody which binds to BFA4 or fragment thereof; and
  - b) determining the binding of BFA4 or fragment thereof and said antibody.
- 15. A method according to Claim 14, wherein said antibody is capable of inhibiting or neutralizing the bioactivity of BFA4.
- 16. A method for inhibiting the activity of BFA4, said method comprising binding an inhibitor to BFA4.
- 17. A method according to claim 16 wherein said inhibitor is an antibody.
- 20 18. A method of neutralizing the effect of BFA4 or a fragment thereof, comprising contacting an agent specific for said BFA4 or fragment thereof with said BFA4 or fragment thereof in an amount sufficient to effect neutralization.
  - A method of treating breast cancer comprising administering to a patient an inhibitor of BFA4.

- 21. A method for localizing a therapeutic moiety to breast cancer tissue comprising exposing said tissue to an antibody to BFA4 or fragment thereof conjugated to said therapeutic moiety.
- 22. The method of Claim 21, wherein said therapeutic moiety is a cytotoxic agent.
- 5 23. The method of Claim 21, wherein said therapeutic moiety is a radioisotope.
  - 24. A method of treating breast cancer comprising administering to an individual having said breast cancer an antibody to BFA4 or fragment thereof conjugated to a therapeutic moiety.
  - 25. The method of Claim 24, wherein said therapeutic moiety is a cytotoxic agent.
  - 26 The method of Claim 24, wherein said therapeutic moiety is a radioisotope.
  - 727. A method for inhibiting breast cancer in a cell, wherein said method comprises administering to a cell a composition comprising aptisense molecules to a nucleic acid of figure 1.
  - 28. A biochip comprising one or more nucleic acid segments encoding BFA4 or a fragment thereof, wherein said biochip comprises fewer than 1000 nucleic acid probes.
  - 29. A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising BFA4 or a fragment thereof.
  - 30. A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising a nucleic acid encoding BFA4 or a fragment thereof.
- 31. A method for determining the prognosis of an individual with breast cancer comprising
  determining the level of BFA4 in a sample, wherein a high level of BFA4 indicates a poor prognosis.

KUVB1